{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:55Z","timestamp":1792783315569,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"ViiV Healthcare","id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03703-3","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:09:55Z","timestamp":1784876995000},"page":"4870-4893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Acting Cabotegravir Injections Are More Acceptable Than Long-Acting Lenacapavir Injections After One Dose: Results From the CLARITY Randomized Crossover Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Emilie R.","family":"Elliot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Boles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dainielle","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Dupont-Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apinya","family":"Vutikullird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Mottola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryakant","family":"Somvanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Strano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanlesta","family":"Pilgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Borsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Budnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony P.","family":"Garges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"S1","key":"3703_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1017\/jme.2022.30","volume":"50","author":"A Killelea","year":"2022","unstructured":"Killelea A, Johnson J, Dangerfield DT, et al. Financing and delivering pre-exposure prophylaxis (PrEP) to end the HIV epidemic. J Law Med Ethics. 2022;50(S1):8\u201323.","journal-title":"J Law Med Ethics"},{"issue":"4","key":"3703_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/QAI.0000000000003370","volume":"95","author":"S Keddem","year":"2024","unstructured":"Keddem S, Thatipelli S, Caceres O, Roder N, Momplaisir F, Cronholm P. Barriers and facilitators to long-acting injectable HIV pre-exposure prophylaxis implementation in primary care since its approval in the United States. J Acquir Immune Defic Syndr. 2024;95(4):370\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3703_CR3","doi-asserted-by":"publisher","first-page":"232595822110090","DOI":"10.1177\/23259582211009011","volume":"20","author":"KK Scarsi","year":"2021","unstructured":"Scarsi KK, Swindells S. The promise of improved adherence with long-acting antiretroviral therapy: what are the data? J Int Assoc Provid AIDS Care. 2021;20:23259582211009012.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"2","key":"3703_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkab324","volume":"77","author":"P Thoueille","year":"2021","unstructured":"Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2021;77(2):290\u2013302.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"3703_CR5","doi-asserted-by":"publisher","first-page":"e26107","DOI":"10.1002\/jia2.26107","volume":"26","author":"L Lorenzetti","year":"2023","unstructured":"Lorenzetti L, Dinh N, van der Straten A, et al. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition. J Int AIDS Soc. 2023;26(Suppl 2):e26107.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"3703_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5729","volume":"33","author":"CD McCormick","year":"2024","unstructured":"McCormick CD, Sullivan PS, Qato DM, Crawford SY, Schumock GT, Lee TA. Adherence and persistence of HIV pre-exposure prophylaxis use in the United States. Pharmacoepidemiol Drug Saf. 2024;33(1):e5729.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"3703_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf220","volume":"12","author":"D Dandachi","year":"2025","unstructured":"Dandachi D, Garris C, Richardson D, et al. Clinical outcomes and perspectives of people with human immunodeficiency virus type 1 twelve months after initiation of long-acting cabotegravir and rilpivirine in an observational real-world US study (BEYOND). Open Forum Infect Dis. 2025;12(5):ofaf220.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"3703_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/cid\/ciae523","volume":"80","author":"C Orkin","year":"2025","unstructured":"Orkin C, Hayes R, Haviland J, et al. Perspectives of people with hiv on implementing long-acting cabotegravir plus rilpivirine in clinics and community settings in the United Kingdom: results from the antisexist, antiracist, antiageist implementing long-acting novel antiretrovirals study. Clin Infect Dis. 2025;80(5):1103\u201313.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3703_CR9","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24(12):3533\u201344.","journal-title":"AIDS Behav"},{"key":"3703_CR10","unstructured":"Felizarta F, Gutner C, Jonsson-Oldenb\u00fcttel C, et al. The power of choice: strong preference for CAB+RPV LA following rapid suppression with DTG\/3TC in ART-naive people living with HIV. Presented at IAS 2025; July 13\u201317, 2025; Kigali, Rwanda."},{"key":"3703_CR11","unstructured":"Apretude [prescribing information]; ViiV Healthcare; 2025."},{"key":"3703_CR12","unstructured":"Apretude [summary of product characteristics]; ViiV Healthcare BV; 2023."},{"key":"3703_CR13","doi-asserted-by":"crossref","unstructured":"Mills AM, Brunet L, Frost KR, et al. Cabotegravir long-acting for PrEPReal world data on on-time dosing, HIV testing and HIV acquisition from the OPERA cohort. Presented at IDWeek 2024; October 16\u201319, 2024; Los Angeles, CA. Oral presentation 508.","DOI":"10.1093\/ofid\/ofae631.160"},{"key":"3703_CR14","doi-asserted-by":"crossref","unstructured":"Ramgopal M, Brown C, Frick A, et al. Real-world use of cabotegravir long-acting for pre-exposure prophylaxis (PrEP): data from trio health cohort. Presented at IDWeek 2024; October 16\u201319, 2024; Los Angeles, CA. Oral presentation 505.","DOI":"10.1093\/ofid\/ofae631.157"},{"issue":"10337","key":"3703_CR15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"issue":"7","key":"3703_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"issue":"13","key":"3703_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"CF Kelley","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261\u201376.","journal-title":"N Engl J Med"},{"issue":"13","key":"3703_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker LG, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179\u201392.","journal-title":"N Engl J Med"},{"key":"3703_CR19","unstructured":"Yeztugo [prescribing information]; Gilead Sciences; 2025."},{"key":"3703_CR20","unstructured":"Yeytuo. [Summary of product characteristics]. Gilead Sciences; 2025; Carrigtohill, Ireland."},{"key":"3703_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03591-7","author":"N Hawkins","year":"2026","unstructured":"Hawkins N, Hazra A, Brizzi M, et al. Indirect treatment comparison of the efficacy of long-acting injectable cabotegravir compared with lenacapavir for HIV pre-exposure prophylaxis. Adv Ther. 2026. https:\/\/doi.org\/10.1007\/s12325-026-03591-7.","journal-title":"Adv Ther"},{"key":"3703_CR22","unstructured":"Vocabria [summary of product characteristics]. Amersfoort, Netherlands: ViiV Healthcare BV; 2025."},{"key":"3703_CR23","unstructured":"Cabenuva [package insert]. Durham, NC: ViiV Healthcare; 2025."},{"key":"3703_CR24","unstructured":"Sulenca [prescribing information]; Gilead Sciences; 2024."},{"issue":"11","key":"3703_CR25","doi-asserted-by":"publisher","first-page":"ofaf651","DOI":"10.1093\/ofid\/ofaf651","volume":"12","author":"P Saberi","year":"2025","unstructured":"Saberi P, McAnaney C, Nakayoshi A, Bositis C, Gandhi M, Chu C. Lenacapavir plus cabotegravir as combination treatment: real-world use cases from the national clinician consultation center. Open Forum Infect Dis. 2025;12(11):ofaf651.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"3703_CR26","doi-asserted-by":"publisher","first-page":"ofav125","DOI":"10.1093\/ofid\/ofae125","volume":"11","author":"M Gandhi","year":"2024","unstructured":"Gandhi M, Hill L, Grochowski J, et al. Case series of people With HIV on the long-acting combination of lenacapavir and cabotegravir: call for a trial. Open Forum Infect Dis. 2024;11(4):ofav125.","journal-title":"Open Forum Infect Dis"},{"key":"3703_CR27","unstructured":"Gistand N, Mishra I, Heise M, et al. Initiating long-acting lenacapavir in a cohort of PWH with high baseline resistance: a case series. Presented at the conference for retroviruses and opportunistic infections; February 22\u201325, 2026; Denver CO. Poster 582."},{"issue":"9","key":"3703_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26003","volume":"25","author":"M Czarnogorski","year":"2022","unstructured":"Czarnogorski M, Garris CP, Dalessandro M, et al. Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE). J Int AIDS Soc. 2022;25(9):e26003.","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"3703_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/phar.2921","volume":"44","author":"EM Sherman","year":"2024","unstructured":"Sherman EM, Agwu AL, Ambrosioni J, et al. Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: an executive summary. Pharmacotherapy. 2024;44(7):488\u201393.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"3703_CR30","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S2352-3018(23)00079-6","volume":"10","author":"JE Haberer","year":"2023","unstructured":"Haberer JE, Mujugira A, Mayer KH. The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities. The Lancet HIV. 2023;10(6):e404\u201311.","journal-title":"The Lancet HIV"},{"issue":"1","key":"3703_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12913-021-06214-9","volume":"21","author":"A Mantsios","year":"2021","unstructured":"Mantsios A, Murray M, Karver TS, et al. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. BMC Health Serv Res. 2021;21(1):255.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"3703_CR32","doi-asserted-by":"publisher","first-page":"ofav282","DOI":"10.1093\/ofid\/ofae282","volume":"11","author":"P Teichner","year":"2024","unstructured":"Teichner P, Chamay N, Elliot E, et al. Cabotegravir + rilpivirine long-acting: overview of injection guidance, injection site reactions, and best practices for intramuscular injection administration. Open Forum Infect Dis. 2024;11(6):ofav282.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"3703_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41120-025-00108-4","volume":"11","author":"L Zhi","year":"2025","unstructured":"Zhi L, Liu D, Shameem M. Injection site reactions of biologics and mitigation strategies. AAPS Open. 2025;11(5):5.","journal-title":"AAPS Open"},{"issue":"10","key":"3703_CR34","doi-asserted-by":"publisher","first-page":"ofaf600","DOI":"10.1093\/ofid\/ofaf600","volume":"12","author":"KA Christopoulos","year":"2025","unstructured":"Christopoulos KA, Erguera X, Grochowski J, et al. Discontinuation of long-acting injectable cabotegravir-rilpivirine in a large clinic cohort. Open Forum Infect Dis. 2025;12(10):ofaf600.","journal-title":"Open Forum Infect Dis"},{"key":"3703_CR35","unstructured":"Phase 1, Open-label, randomised crossover study assessing the tolerability and acceptability of long acting cabotegravir intramuscular and lenacapavir subcutaneous injections over time in healthy adults without HIV. https:\/\/clinicaltrials.gov\/study\/NCT06970223."},{"key":"3703_CR36","unstructured":"Centers for Disease Control and Prevention. Clinical Guidance for PrEP. Available at https:\/\/www.cdc.gov\/hivnexus\/hcp\/prep\/index.html. Accessed 27 Apr 2026."},{"issue":"1","key":"3703_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7525-7-21","volume":"7","author":"C Chevat","year":"2009","unstructured":"Chevat C, Viala-Danten M, Dias-Barbosa C, Nguyen VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees\u2019 Perception of Injection (VAPI\u00a9) questionnaire. Health Qual Life Outcomes. 2009;7(1):21.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"3703_CR38","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1007\/s12325-023-02656-1","volume":"40","author":"V Chounta","year":"2023","unstructured":"Chounta V, Byrnes HF, Henry-Szatkowski M, Browning D, Donatti C, Lambert J. Psychometric validation of the perception of injection (PIN) questionnaire using data from two phase III, open-label, active-controlled, non-inferiority studies in people living with HIV. Adv Ther. 2023;40(12):5300\u201314.","journal-title":"Adv Ther"},{"key":"3703_CR39","unstructured":"Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events CV. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf. Accessed 9 Feb 2024."},{"issue":"12","key":"3703_CR40","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1089\/aid.2020.0107","volume":"36","author":"K Dub\u00e9","year":"2020","unstructured":"Dub\u00e9 K, Campbell DM, Perry KE, et al. Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options. AIDS Res Hum Retroviruses. 2020;36(12):1054\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"3703_CR41","doi-asserted-by":"crossref","unstructured":"Holder H, Pilgrim N, Oritz R, et al. Patient experiences at month 6 after initiation of cabotegravir long-acting (CAB LA) For PrEP in the first male gender concordant implementation science trial (PILLAR) in the United States. IDWeek 2024, 2024; Los Angeles, CA.","DOI":"10.1093\/ofid\/ofae631.1599"},{"key":"3703_CR42","doi-asserted-by":"crossref","unstructured":"Nelson KL, Tims-Cook Z, Kwakwa H, et al. Black women\u2019s experiences on long-acting cabotegravir for PrEP: interim patient findings from the EBONI study. IDWeek 2025, 2025; Atlanta, GA.","DOI":"10.1093\/ofid\/ofaf695.532"},{"key":"3703_CR43","unstructured":"Mngadi K, Phanuphak N, Hinojosa JC, et al. Preference for twice-yearly injections vs. daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men, and gender nonbinary people enrolled in PURPOSE 2. Presented at 13th International AIDS Society (IAS) Conference on HIV Science; July 13\u201317, 2025; Kigali, Rwanda. Oral presentation C0502."},{"key":"3703_CR44","unstructured":"Clement ME, Wang Z, Fichtenbaum CJ, et al. Pre-exposure prophylaxis product choice of participants in HPTN 083. Presented at the 25th International AIDS Conference; July 22\u201326, 2024; Munich, Germany. Poster TUPEC184."},{"key":"3703_CR45","unstructured":"Delany-Moretlwe S, Hanscom B, Angira F, et al. Initial PrEP product choice: results from the HPTN 084 open-label extension. Prsented at AIDS 2023; July 23\u201326, 2023; Brisbane, Australia. Oral Presentation OALBX0203."},{"key":"3703_CR46","unstructured":"Mansoor LE, Lebina L, Makhoba P, et al. Predictors of HIV pre-exposure prophylaxis preferences using the health belief model: twice-yearly subcutaneous lenacapavir versus daily pills in the PURPOSE 1 Trial. Presented at 13th International AIDS Society (IAS) Conference on HIV Science; July 13\u201317, 2025; Kigali, Rwanda. Poster TUBEC057."},{"key":"3703_CR47","volume-title":"incorporating voluntary patient preference information over the total product life cycle","author":"US Food and Drug Administration","year":"2024","unstructured":"US Food and Drug Administration. incorporating voluntary patient preference information over the total product life cycle. US Food and Drug Administration; 2024."},{"issue":"7","key":"3703_CR48","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpdd.1538","volume":"14","author":"K Han","year":"2025","unstructured":"Han K, Benn P, Sievers J, et al. A randomized phase 1 study evaluating pharmacokinetics, safety, and tolerability of a high-concentration, long-acting cabotegravir formulation in adults without HIV. Clin Pharmacol Drug Dev. 2025;14(7):528\u201341.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03703-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:42Z","timestamp":1790609982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03703-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3703"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03703-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Justine Boles, Emilie Elliot, Dainielle Fox, Nanlesta Pilgrim, Rebecca Borsi, Piotr Budnik, Jean van Wyk, and Kimberley Brown are employees of ViiV Healthcare and may hold stock in GSK. Katherine L. Nelson was an employee of ViiV Healthcare at the time of this work and may hold stock in GSK and is now an employee of and holds stock in Merck. Apinya Vutikullird has received travel support for Investigator meetings from Akero Therapeutics, AstraZeneca, Boehringer Ingelheim, 89bio, Eli Lilly, Regeneron, and Viking. Kim Fletcher, Kehui Wang, Suryakant Somvanshi, Richard Grove, and Harmony P. Garges are employees of and hold stock in GSK. Laure Dupont-Benjamin is an employee of ViiV Healthcare; owns stock in AbbVie, GSK, Haleon, and ViiV Healthcare; and has received consulting fees from the International Union Against Tuberculosis and Lung Disease. Amber Mottola and Katie Strano have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with legal and regulatory requirements and the principles in the Declaration of Helsinki and the Council for International Organizations of Medical Sciences international ethical guidelines. An institutional review board reviewed and approved the study protocol and other relevant documents (Advarra IRB: Pro00085558, approved March 19, 2025), and all participants provided written informed consent before study enrollment.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}